 |
40 Products |  |
109 Diseases | | 40 Products |
|
37 Trials |  |
1900 News |  |
| «12345678910111213...1920» |
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A North west London experience of use of Immunotherapeutic drugs in advanced renal cancer during COVID-19 pandemic ([VIRTUAL]) - Nov 16, 2021 - Abstract #NCRI2021NCRI_154;
209 patients with aRCC were treated at these centres and all patients had either received an oral tyrosine kinase inhibitor (TKI’S-pazopanib, sunitinib, cabozantinib, tivozanib) or levantinib/ everolimus combination, or ipilimumab/ nivolumab or axitinib/avelumab or nivolumab single agent...Our centre was able to provide optimum therapy to all patients with aRCC during the COVID-19 pandemic. Impact statement Patients with aRCC should not be denied novel immunotherapy combinations in 1st line setting, during the COVID-19 pandemic.
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
Tivozanib as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC) – A real-world outcome review in North-West of England (NWE), UK (Strategy stage; Research stage; Fringe stage [VIRTUAL]) - Nov 16, 2021 - Abstract #NCRI2021NCRI_128;
The lower incidence of serious AEs makes it an attractive option if unsuitable for combination therapies. Impact statement This large real-world data set strengthens the case for considering the use of Tivozanib in selected patients.
- | LC51-0255 / LG Chem
Enrollment change, Trial withdrawal: Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Nov 15, 2021
P2, N=0, Withdrawn, Sponsor: LG Chem
Impact statement This large real-world data set strengthens the case for considering the use of Tivozanib in selected patients. N=240 --> 0 | Not yet recruiting --> Withdrawn
- | Shinbaro (GCSB-5) / GC Pharma, LG Chem
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: The Effectiveness of Megadose Shinbaro Pharmacopuncture for Patients With Chronic Shoulder Pain (clinicaltrials.gov) - Nov 8, 2021
P=N/A, N=36, Terminated, Sponsor: Jaseng Medical Foundation
N=240 --> 0 | Not yet recruiting --> Withdrawn N=80 --> 36 | Trial completion date: Dec 2021 --> Jun 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Jun 2021; low participate rate
- || AV-203 / AVEO
Clinical, Journal: Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study. (Pubmed Central) - Nov 4, 2021
Elevated FFA in obese with normal glycaemia were better explained by increased fat mass rather than by adipose tissue insulin resistance. These results support the idea that hyperinsulinemia and insulin resistance may develop as part of a homeostatic adaptive response to increased adiposity and FFA.
- || Clinical, Journal: First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. (Pubmed Central) - Oct 31, 2021
Significant inter-expert variations were observed. This demonstrates how data from randomized trials are implemented differently when transferred into daily practice.
- || Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. (Pubmed Central) - Oct 29, 2021
P3
This demonstrates how data from randomized trials are implemented differently when transferred into daily practice. Q-TWiST may be considered an alternative patient-centered measure of benefit of tivozanib in as a third- or fourth-line therapy in patients with renal cell carcinoma.
- || Gemiglo (gemigliptin) / Sanofi, LG Chem
Clinical, Journal, Monotherapy: A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus. (Pubmed Central) - Oct 27, 2021
For the pbo-gemi group, HbA1c decreased after they were switched to gemigliptin, and the mean change in HbA1c at week 52 from baseline was -0.7%±1.2% (P<0.0001). Furthermore, the overall incidence of adverse events demonstrated that gemigliptin was safe and well tolerated up to 52 weeks.
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer. (Pubmed Central) - Oct 27, 2021
Following the discovery of MET as a potential therapeutic target, extensive clinical studies have proposed three approaches to targeting MET: (1) MET tyrosine kinase inhibitors (TKIs), including crizotinib, capmatinib, tepotinib, savolinitib, and cabozantinib; (2) MET or HGF monoclonal antibodies, including emibetuzumab and ficlatuzumab; and (3) MET or HGF antibody drug conjugates, including telisotuzumab. Herein, we discuss the relevant clinical trials, particularly focusing on the efficacy as well as the safety and tolerability of the treatment options, in the promising field of targeting MET in NSCLC.
- | Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Journal: Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery. (Pubmed Central) - Oct 25, 2021
Multiple small molecule inhibitors of the VEGFR-2 are approved for the treatment of different type of cancers, with one of the most recent, tivozanib, being approved by the FDA for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC)...We applied a combination of computational methods and approaches for drug design and discovery with the goal of finding novel, potential and small molecule inhibitors of VEGFR2, as alternatives to the known inhibitors' chemical scaffolds and components. From studying several of these compounds, the derivatives of pyrido[1,2-a]pyrimidin-4-one and isoindoline-1,3-dione in particular were identified.
- Besivo (besifovir) / Gilead, LG Chem, Ildong
[VIRTUAL] SAFETY AND EFFICACY OF SWITCHING TO BESIFOVIR DIPIVOXIL MALEATE IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH TENOFOVIR DISOPROXIL FUMARATE: A RANDOMIZED CONTROLLED TRIAL () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1036;
From studying several of these compounds, the derivatives of pyrido[1,2-a]pyrimidin-4-one and isoindoline-1,3-dione in particular were identified. In virologically suppressed CHB patients who switched to BSV from TDF, the BSV group demonstrated non-inferior antiviral efficacy compared to the TDF group and improved safety.
- Besivo (besifovir) / Gilead, LG Chem, Ildong, Vemlidy (tenofovir alafenamide) / Gilead
[VIRTUAL] A NATIONWIDE PROSPECTIVE COHORT STUDY ON CHRONIC HEPATITIS B IN KOREA: AN INTERIM ANALYSIS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_958;
This longitudinal cohort study covering Korean CHB patients sufficiently reflected current antiviral strategies for Korean patients with CHB and showed the sufficient efficacy for treating these patients. Future researches using this cohort and corresponding blood samples may reveal new requirements for CHB treatment.
- | GEN-001 / Genome & Company
New trial, Metastases: Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Oct 14, 2021
P=N/A, N=40, Not yet recruiting, Sponsor: Korean Cancer Study Group
- || Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem, Tecentriq (atezolizumab) / Roche
Enrollment open: IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov) - Oct 13, 2021
P1/2, N=29, Recruiting, Sponsor: University of Florida
Future researches using this cohort and corresponding blood samples may reveal new requirements for CHB treatment. Not yet recruiting --> Recruiting
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Trial completion date: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Oct 12, 2021
P2, N=31, Completed, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> May 2021
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion date, Trial primary completion date: Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (clinicaltrials.gov) - Oct 10, 2021
P1/2, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> May 2021 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- || ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
Clinical, PK/PD data, Journal: Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. (Pubmed Central) - Oct 10, 2021
The FDC of gemigliptin/rosuvastatin 50/20 mg as the bilayer tablet showed equivalent PK and PD properties with the FDC of gemigliptin/rosuvastatin 50/20 mg as the monolayer tablet in healthy subjects. These results suggest that the newly developed bilayer tablet can become an alternative formulation to the commercially available monolayer tablet.
- CUE-102 / Cue Biopharma, LG Chem
CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1086;
Conclusions CUE-102 elicits selective expansion of a WT1-specific population of cytotoxic CD8+ T cells both in vitro and in vivo. These results, together with its similarity to CUE-101, support its anticipated tolerability profile and potential for clinical efficacy in a Phase 1 trial planned to initiate in 2022.
- Keytruda (pembrolizumab) / Merck (MSD), CUE-101 / Cue Biopharma, LG Chem
A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_965;
P1
Conclusions CUE-101 is a novel immunotherapeutic demonstrating acceptable safety and tolerability with encouraging PD signals, supporting selective activation of tumor-specific T cells, and promising antitumor activity. Enrollment continues in both monotherapy and combination cohorts.
- CUE-101 / Cue Biopharma, LG Chem
Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platforms (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_580;
Emerging clinical data from our lead candidate CUE-101, which targets HPV-specific T cells in 2L+ R/M HNSCCC, provides PoC for the approach and builds confidence for broad applications in numerous cancers...Conclusions The IST, NST, and RDI-STAT platforms provide novel opportunities for selective targeting of IL-2 to tumor-relevant T cells while avoiding global immune activation and cytokine release. The scalability and versatility of NSTs highlight the potential to target multiple TAA T cell responses, while RDI-STATs highlight a novel means to harness antiviral immunity against cancer, especially in cases where the tumor may escape immune detection due to loss of HLA.
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_377;
P3
Prior IO was associated with less asthenia overall, more HTN with TIVO, and more rash but less diarrhea with SOR Conclusions Tolerability benefits with TIVO compared to SOR in mRCC are retained in elderly patients and those previously treated with IO. This finding, paired with consistently improved PFS in these subpopulations (age >65: HR 0.59, prior IO: HR 0.55), suggests TIVO is a safe and effective option in the context of the current R/R mRCC treatment paradigm ClinicalTrials gov Identifier: NCT02627963
- | Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Journal: Tivozanib Hydrochloride. (Pubmed Central) - Oct 1, 2021
This finding, paired with consistently improved PFS in these subpopulations (age >65: HR 0.59, prior IO: HR 0.55), suggests TIVO is a safe and effective option in the context of the current R/R mRCC treatment paradigm ClinicalTrials gov Identifier: NCT02627963 No abstract available
- | Retrospective data, Review, Journal: Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 29, 2021
As a class, DPP4i are not associated with any increase or reduction of MACE, all-cause mortality, and heart failure. Saxagliptin seems to be associated with an increased risk of hospitalization for heart failure.
- ||| Besivo (besifovir) / Gilead, LG Chem, Ildong
P3 data, Journal: Continuing Besifovir Dipivoxil Maleate Versus Switching from Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B: Results of 192-Week Phase 3 Trial. (Pubmed Central) - Sep 24, 2021
P3
BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).
- |||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment open, Combination therapy, Monotherapy, Checkpoint inhibition: TiNivo-2: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma (clinicaltrials.gov) - Sep 23, 2021
P3, N=326, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Trial Registration Number: NCT01937806 (date: 10 Sep 2013). Not yet recruiting --> Recruiting
- | AV-203 / AVEO
Journal: Structure-based Virtual Screening and Molecular Dynamics Simulation Studies to Discover New SARS-CoV-2 Main Protease Inhibitors. (Pubmed Central) - Sep 21, 2021
Computational methods were used to filter two datasets (> 8,000 compounds) based on two criteria: higher binding affinity for M than cocrystallized inhibitor and binding interactions with M catalytic dyad (Cys145 and His41). After virtual screening involving ranking and reranking, eleven compounds were identified to satisfy these criteria and analysis of their structures revealed an unparallel common features among them which could be critical for their interactions with M. However, only the topmost scoring compound (AV-203: K = 0.31 µM) exhibited relatively stable binding interaction during the period of 50 ns MD simulation and thus is a suitable template for drug development.
- || ficlatuzumab (AV-299) / AVEO
Clinical, Clinical data, Journal, Combination therapy: Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. (Pubmed Central) - Sep 14, 2021
The ficlatuzumab and cytarabine combination is well-tolerated with favorable efficacy. High-dimensional analyses at single-cell resolution represent promising approaches for identifying biomarkers of response and mechanisms of resistance in prospective clinical studies.
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Combination therapy, Metastases: DEDUCTIVE: A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 9, 2021
P1b/2, N=42, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
High-dimensional analyses at single-cell resolution represent promising approaches for identifying biomarkers of response and mechanisms of resistance in prospective clinical studies. Trial primary completion date: Aug 2021 --> Aug 2022
- || Retrospective data, Review, Journal: A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. (Pubmed Central) - Sep 8, 2021
Regarding safety, avelumab + axitinib and temsirolimus were considered preferred treatment options in first-line and second-line therapies. More future research is needed to establish subgroup analyses, allowing evaluation of the impact of some of the differences in patient characteristics, including treatment effect modifiers.
- | Verquvo (vericiguat) / Bayer, Merck (MSD), Tepmetko (tepotinib) / EMD Serono, Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Journal: New Drugs. (Pubmed Central) - Sep 5, 2021
More future research is needed to establish subgroup analyses, allowing evaluation of the impact of some of the differences in patient characteristics, including treatment effect modifiers. The manuscript contains description of three new medications (vericiguat, tepotinib, tivozanib) which were approved by the US Federal Drug Administration in 2021 and can be used in older populations.
- | ICM-203 / Yonsei Technology Holdings
Trial initiation date: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - Aug 24, 2021
P1/2, N=24, Not yet recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
The manuscript contains description of three new medications (vericiguat, tepotinib, tivozanib) which were approved by the US Federal Drug Administration in 2021 and can be used in older populations. Initiation date: Jun 2021 --> Sep 2021
- ||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Enrollment closed, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study) (clinicaltrials.gov) - Aug 23, 2021
P3, N=315, Active, not recruiting, Sponsor: LG Chem
Initiation date: Jun 2021 --> Sep 2021 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jan 2022 --> May 2021
- ||||| ficlatuzumab (AV-299) / AVEO
Clinical: Small phase-1 study showed high rate of complete remissions in relapsed/refractory acute myeloid leukemia treated with combination of ficlatuzumab plus chemotherapy Read more here https://t.co/MwuImxsCll (Twitter) - Aug 13, 2021
- || Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem, Tecentriq (atezolizumab) / Roche
New P1/2 trial: IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov) - Aug 10, 2021
P1/2, N=29, Not yet recruiting, Sponsor: University of Florida
- || ficlatuzumab (AV-299) / LG Chem
Trial completion, Trial completion date, Metastases: Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 3, 2021
P1b, N=26, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jan 2022 --> May 2021 Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Jul 2021
- |||||||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P3 trial, Combination therapy, Monotherapy, Checkpoint inhibition: TiNivo-2: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma (clinicaltrials.gov) - Aug 3, 2021
P3, N=326, Not yet recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- || DTwP-HepB / LG Chem
Clinical, Journal, HEOR: Vaccination in children under 1 year with pertussis component in the context of the global initiative for the eradication of poliomyelitis in Argentina: economic analysis (Pubmed Central) - Jul 28, 2021
Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Jul 2021 Full IPV introduction investment and costs associated were modified according to the type of vaccine and reactogenicity related with the B. pertussis component.
- ||||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jul 27, 2021
P3, N=350, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Full IPV introduction investment and costs associated were modified according to the type of vaccine and reactogenicity related with the B. pertussis component. Active, not recruiting --> Completed
- ||| Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
Clinical, P3 data, Journal: Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. (Pubmed Central) - Jul 24, 2021
PATIENT SUMMARY: We show that tivozanib, a targeted therapy, can delay tumor growth relative to an already approved targeted therapy (sorafenib) in patients with kidney cancer who have received two or three prior treatments. No difference in survival was observed.
- |||||| Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Clinical: Our recent #drug evaluation summarizes the growing evidence of #Tivozanib efficacy @DrTHut @TexasOncology #kcsm 📖 "Tivozanib, a highly potent and selective inhibitor of #VEGF receptor tyrosine kinases, for the treatment of #metastatic #renalcellcarcinoma" https://t.co/RD1nalFQzd (Twitter) - Jul 22, 2021
- ||| TNFcept (etanercept biosimilar) / LG Chem, Mochida, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
10/ The other conclusion I query is the Adalimumab vs etanercept comparison. Increased risk disappears when cohort restricted to those without psoriatic arthritis/inflammatory bowel disease. Add to the increased risk in concomitant NSAID use (not biologically plausible)... (Twitter) - Jul 22, 2021
- |||| Clinical: 3/ And looked for the risk of serious infection, defined by first hospital discharge diagnosis for an infection, in new users of medications Main findings: Adalimumab, infliximab > etanercept Ustekinumab < etanercept Unclear about other treatments as small groups (Twitter) - Jul 22, 2021
- ||| TNFcept (etanercept biosimilar) / LG Chem, Mochida, Enbrel (etanercept) / Pfizer, Amgen
Clinical, Monotherapy: #ACRJournalClub @cmsungur1 Your article mentioned the potential for immunogenicity (anti-drug antibodies) that might form in patients on TNFi monotherapy. But do you really think that’s an issue for a molecule like #etanercept? (Twitter) - Jul 21, 2021
- ||| TNFcept (etanercept biosimilar) / LG Chem, Mochida, Enbrel (etanercept) / Pfizer, Amgen
Clinical, Monotherapy: #ACRJournalClub In SEAM-RA, time to disease worsening was shorter (worse) in the MTX monotherapy group vs. etanercept (p < 0.001). In all 3 arms, the majority of patients who worsened/flared were able to be recaptured back to remission or at least low disease activity. (Twitter) - Jul 21, 2021
- |||| TNFcept (etanercept biosimilar) / LG Chem, Mochida, Enbrel (etanercept) / Pfizer, Amgen
Clinical, Clinical data: #ACRJournalClub SEAM-RA study randomized 371 #rheumatoid arthritis patients on #etanercept and #methotrexate to discontinue one of them. Results showed that patients stopping MTX and continuing ETA had better clinical outcomes (Twitter) - Jul 21, 2021
- |||| TNFcept (etanercept biosimilar) / LG Chem, Mochida, Enbrel (etanercept) / Pfizer, Amgen
Clinical, Clinical data: Glad to have the opportunity to talk about the SEAM-RA study that randomized 371 #rheumatoid arthritis patients on #etanercept and #methotrexate to discontinue one of them. Results showed that patients stopping MTX and continuing ETA had better clinical outcomes #ACRJournalClub (Twitter) - Jul 21, 2021
- ||| TNFcept (etanercept biosimilar) / LG Chem, Mochida, Enbrel (etanercept) / Pfizer, Amgen
Clinical: ⭐️ Tonight at 7pm ET will be our first #ACRJournalClub with authors @cmsungur2 & @RADoctor Articles: 1. Sustained Remission in RA: Time to Withdraw Treatment? https://t.co/R9O4MeCZwO 2. Etanercept or MTX Withdrawal in RA Patients in Sustained Remission https://t.co/zS5XaoMih1 (Twitter) - Jul 21, 2021
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Preclinical, Journal: Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats. (Pubmed Central) - Jul 21, 2021
Therefore, gemigliptin has protective roles against salivary dysfunction observed in diabetes, mediated via antioxidant, anti-apoptotic, and salivary secretion mechanisms. These results may help in selecting a suitable drug for patients with diabetes experiencing salivary dysfunction.